QUEBEC CITY, May 20, 2015 /CNW Telbec/ - DiagnoCure Inc. (TSX: CUR; OTCQX: DGCRF) (the "Corporation") today reports that the results of the prospective trial on its prostate cancer panel (PCP) urine test were well received by the urologist community attending the 2015 Annual Meeting of the American Urological Association (AUA) held from May 15 to May 19 in New Orleans, Louisiana.
DiagnoCure's presentation titled "Validated Urine-based Multigene Signature for Detection of Aggressive Prostate Cancer" had been chosen to be included in the 2015 AUA Press Program about the use of imaging and urine-based biomarkers as ways to improve prostate cancer detection. Following a rigorous selection process, including a review by a panel of Public Media Committee members and AUA Communications Department staff, DiagnoCure's presentation was one of fewer than 45 presentations, among more than 2,500 at this year's AUA annual meeting, selected for discussion with the media. As part of this great honor, Dr. Yves Fradet was given the opportunity to speak with reporters about the PCP Risk Score at a press conference held on Monday May 18, 2015.
The data presented highlight how the use of this new urine-based test developed by Diagnocure can improve the detection of higher-grade cancers to optimize clinical decisions relative to first or repeat biopsies. An analysis of the performance of the PCP Risk Score in the validation study (503 men) showed that one out of three men had a PCP Risk Score greater than 60, and were classified at very high risk of aggressive prostate cancer. Men with a score less than 20 had only an 8 percent risk of high-grade disease.
"We believe that our new test which helps detect the potential presence of prostate cancer as well as its aggressiveness was a long awaited test in the clinical community. A number of tests are currently available but few can really have this ability of detecting non-invasively potentially lethal prostate cancers. That information is critical for clinicians to decide if a biopsy is needed. Our test can drastically change the way prostate cancer is diagnosed and treated", stated Dr. Yves Fradet, President and Chief Medical Officer of DiagnoCure. He added: "This is particularly important at a time when controversial recommendations have led to a decline in PSA screening, and consequently, to an increased frequency of delayed detection of advanced prostate cancers".
About the PCP Risk Score Test
The PCP Risk Score Test is the Corporation's newly developed multimarker prostate cancer urine test to accurately identify risk of aggressive cancer prior to biopsy. The test was developed and validated in 764 men referred to prostate biopsy based on elevated PSA. The PCP Risk Score test examined genes from multiple biological pathways whose altered expression in urine was associated with detection of aggressive prostate cancer. Combination of this panel of urine-based biomarkers with established risk factors (age, abnormal findings on rectal examination or prior biopsy history) using a proprietary algorithm allows calculation of the probability of finding an aggressive prostate cancer. The resulting PCP Risk Score test thus provides individualized risk assessment and adds new information that might help physicians and their patients decide whether or not a prostate biopsy is required.
DiagnoCure (TSX: CUR; OTCQX: DGCRF) is a life sciences corporation that develops and provides molecular and genomic tests to support effective clinical decisions enabling personalized medicine in oncology. Previstageâ GCC and the PCP Risk Score test are currently available for licensing. The Corporation has granted a worldwide exclusive license on the diagnostic applications of PCA3 for the development and commercialization of a prostate cancer test which is commercialized in Europe under CE mark and approved for commercialization in Canada and the United States. For more information, please visit www.diagnocure.com.
This release may contain forwardlooking statements that involve known and unknown risks, uncertainties and assumptions that may cause actual results to differ materially from those expected. Forward-looking statements can be identified by the use of the conditional or forward-looking terminology such as "anticipates", "assumes", "believes", "estimates", "expects", "intend", "may", "plans", "projects", "should", "will", or the negative thereof or other variations thereon. Forward-looking statements also include any other statements that do not refer to historical facts. All such forward-looking statements are made pursuant to the "safe-harbour" provisions of applicable Canadian securities laws. By their very nature, forwardlooking statements are based on expectations and assumptions and also involve risks and uncertainties, known and unknown, many of which are beyond DiagnoCure's control. Forward-looking statements are presented for the purpose of assisting investors and others in understanding certain key elements of the Corporation's current objectives, strategic priorities, expectations and plans, and in obtaining a better understanding of the Corporation's business and anticipated operating environment. Readers are cautioned that such information may not be appropriate for other purposes and that they should not place undue reliance on these forwardlooking statements. For instance, any forward-looking statements regarding the outcome of research and development projects, clinical studies and future revenues, including those related to PCP Risk Score are based on management expectations and such outcome may vary materially depending on global political and economic conditions, dependence on collaboration partners, uncertainty of healthcare reimbursement, and marketing and distribution challenges. In addition, the reader is referred to the applicable general risks and uncertainties described in DiagnoCure's most recent Annual Information Form under the heading "Risk Factors". DiagnoCure undertakes no obligation to publicly update or revise any forwardlooking statements contained herein unless required by the applicable securities laws and regulations.
SOURCE DiagnoCure inc.
For further information: Investors: DiagnoCure Inc., Frédéric Boivin, Sr. Director. Finances and Administration, (418) 527-6100, email@example.com; Media: DiagnoCure Inc., Danielle Allard, Sr. Director, Corporate Affairs, (418) 527-6100, firstname.lastname@example.org